MY208779A - Means and method for preparing viral vectors and uses of same - Google Patents

Means and method for preparing viral vectors and uses of same

Info

Publication number
MY208779A
MY208779A MYPI2020002052A MYPI2020002052A MY208779A MY 208779 A MY208779 A MY 208779A MY PI2020002052 A MYPI2020002052 A MY PI2020002052A MY PI2020002052 A MYPI2020002052 A MY PI2020002052A MY 208779 A MY208779 A MY 208779A
Authority
MY
Malaysia
Prior art keywords
same
viral vectors
preparing viral
preparing
compositions
Prior art date
Application number
MYPI2020002052A
Inventor
Brian K Kaspar
James Michael Hatfield
Joseph Balleydier
Allan Arman Kaspar
Robert Emil Hodge
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MY208779A publication Critical patent/MY208779A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Manufacturing & Machinery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)

Abstract

Methods for preparing and purifying viral particles, and compositions and uses comprising the same, are provided.
MYPI2020002052A 2017-11-08 2018-11-01 Means and method for preparing viral vectors and uses of same MY208779A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762583035P 2017-11-08 2017-11-08
PCT/US2018/058744 WO2019094253A1 (en) 2017-11-08 2018-11-01 Means and method for preparing viral vectors and uses of same

Publications (1)

Publication Number Publication Date
MY208779A true MY208779A (en) 2025-05-28

Family

ID=64362706

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020002052A MY208779A (en) 2017-11-08 2018-11-01 Means and method for preparing viral vectors and uses of same

Country Status (17)

Country Link
US (2) US12168777B2 (en)
EP (2) EP4585229A3 (en)
JP (2) JP7587422B2 (en)
KR (2) KR20260052185A (en)
CN (4) CN119033965A (en)
AU (3) AU2018365677C1 (en)
BR (1) BR112019013268A2 (en)
CA (2) CA3309109A1 (en)
CL (3) CL2020001193A1 (en)
CO (1) CO2020006900A2 (en)
IL (2) IL274430B2 (en)
MX (3) MX2020004830A (en)
MY (1) MY208779A (en)
SA (1) SA520411930B1 (en)
SG (1) SG11202004406VA (en)
TW (1) TWI827560B (en)
WO (1) WO2019094253A1 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11219696B2 (en) * 2008-12-19 2022-01-11 Nationwide Children's Hospital Delivery of polynucleotides using recombinant AAV9
US20200164008A1 (en) * 2017-07-17 2020-05-28 Spark Therapeutics, Inc. Apheresis methods and uses
EP4585229A3 (en) 2017-11-08 2026-01-14 Novartis AG Means and method for preparing viral vectors and uses of same
JP7478675B2 (en) * 2018-06-08 2024-05-07 ノバルティス アーゲー Cell-Based Assays for Measuring the Potency of Drug Products
JP2021534154A (en) * 2018-08-15 2021-12-09 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. Combination therapy for spinal muscular atrophy
EP3886919A1 (en) * 2018-11-30 2021-10-06 Novartis AG Aav viral vectors and uses thereof
HRP20251506T1 (en) * 2019-04-10 2026-01-02 Prevail Therapeutics, Inc. GENE THERAPY FOR LYSOSOMIC DISORDERS
US10801042B1 (en) * 2019-07-15 2020-10-13 Vigene Biosciences, Inc. Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus
CA3147875A1 (en) 2019-07-19 2021-01-28 Flagship Pioneering Innovations Vi, Llc Recombinase compositions and methods of use
CN114174514A (en) 2019-07-25 2022-03-11 诺华股份有限公司 Adjustable expression system
WO2021026461A2 (en) * 2019-08-08 2021-02-11 Biogen Ma Inc. Potency assays for viral vector production
WO2021087282A1 (en) * 2019-10-30 2021-05-06 Amicus Therapeutics, Inc. Recombinant cdkl5 proteins, gene therapy and production methods
EP4087949A1 (en) * 2020-01-28 2022-11-16 Lonza Walkersville, Inc. Methods of determining viral titer
EP4136231A1 (en) 2020-04-17 2023-02-22 Friedrich Miescher Institute for Biomedical Research Use of an orphan motif to increase expression of a heterologous transgene
RU2742837C1 (en) * 2020-06-02 2021-02-11 Общество С Ограниченной Ответственностью "Анабион" Codon-optimized nucleic acid which encodes smn1 protein, and use thereof
EP4175969A4 (en) * 2020-07-01 2024-07-24 Medimmune, LLC CLEANING AGENTS AND METHOD FOR CLEANING A BIOTHERAPEUTIC PRODUCT
CN112121179A (en) * 2020-09-15 2020-12-25 山东兴瑞生物科技有限公司 Composition and application thereof in treating spinal muscular atrophy
JP2023545830A (en) * 2020-10-15 2023-10-31 プリベイル セラピューティクス,インコーポレーテッド Recombinant adeno-associated virus composition and method for producing the same
CN112251440A (en) * 2020-10-29 2021-01-22 大连理工大学 CRISPR/Cas9 gene vector, and preparation method and application thereof
CN116529381A (en) 2020-12-03 2023-08-01 弗里德里克·米谢尔生物医学研究所 Control of expression of heterologous transgenes using a combination of orphan motifs and CpG density
EP4324907A4 (en) * 2021-04-15 2025-06-18 The University of Tokyo PROCESS FOR PRODUCING VIRAL PARTICLES
US20240254483A1 (en) 2021-07-30 2024-08-01 Tune Therapeutics, Inc. Compositions and methods for modulating expression of frataxin (fxn)
AU2022318664A1 (en) 2021-07-30 2024-02-29 Tune Therapeutics, Inc. Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
JP2024532700A (en) * 2021-08-04 2024-09-10 武田薬品工業株式会社 Adeno-associated virus separation using cation exchangers.
JP2024534410A (en) 2021-09-16 2024-09-20 ノバルティス アーゲー Novel transcription factors
CN118119710A (en) * 2021-10-15 2024-05-31 上海天泽云泰生物医药有限公司 Recombinant adeno-associated virus vector for the treatment of spinal muscular atrophy
JP2024539123A (en) 2021-10-25 2024-10-28 ノバルティス アーゲー Methods for improving adeno-associated virus (AAV) delivery
WO2023085382A1 (en) * 2021-11-12 2023-05-19 Agc株式会社 Virus purification method
US20250001013A1 (en) 2021-11-24 2025-01-02 Novartis Ag Modulators of adeno-associated virus transduction and uses thereof
CA3255627A1 (en) 2022-05-06 2023-11-09 Novartis Ag Novel recombinant aav vp2 fusion polypeptides
EP4554967A2 (en) 2022-07-12 2025-05-21 Tune Therapeutics, Inc. Compositions, systems, and methods for targeted transcriptional activation
CN114990162A (en) * 2022-07-18 2022-09-02 苏州吉纳星辰生物技术有限公司 Method for reducing plasmid residue in production of AAV (adeno-associated virus) viral vector
WO2024027632A1 (en) * 2022-08-01 2024-02-08 Skyline Therapeutics (Shanghai) Co., Ltd. Novel plasmid backbone to reduce dna impurities in raav preparation
CN115354071A (en) * 2022-08-10 2022-11-18 上海药明生基医药科技有限公司 A method for detecting recombinant adeno-associated virus host cell DNA residue
CN116350801A (en) 2022-11-22 2023-06-30 四川至善唯新生物科技有限公司 A pharmaceutical composition of a recombinant adeno-associated virus vector and its application
WO2024163678A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
WO2024163683A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
WO2024194280A1 (en) 2023-03-21 2024-09-26 F. Hoffmann-La Roche Ag Method for the production of recombinant aav particle preparations
WO2024252182A1 (en) * 2023-06-08 2024-12-12 Meiragtx Uk Ii Limited Cation exchange chromatography for aav capture
WO2025157137A1 (en) * 2024-01-25 2025-07-31 鼐济医药科技(杭州)有限公司 Aav vector, vector composition, chimeric vector and method for treating or preventing sma
AU2025218748A1 (en) 2024-02-09 2026-08-06 F. Hoffmann-La Roche Ag Method for producing recombinant adeno-associated viral particles
WO2025188316A1 (en) * 2024-03-08 2025-09-12 Jaguar Gene Therapy, Llc Aav pharmaceutical formulations and methods thereof
WO2025190867A1 (en) * 2024-03-11 2025-09-18 Sartorius Stedim Biotech Gmbh Two-step intensified cell lysis to release a viral vector
WO2025217224A1 (en) * 2024-04-08 2025-10-16 Advanced Medicine Partners, LLC Method of manufacture of aav particles
KR102915956B1 (en) * 2024-04-17 2026-01-20 한국로봇융합연구원 3D orbital welding robot
WO2025252480A1 (en) 2024-06-07 2025-12-11 F. Hoffmann-La Roche Ag Method for purifying plasmid dna
US20260022401A1 (en) 2024-07-22 2026-01-22 Hoffmann-La Roche Inc. Novel AAV rep ORFs and Rep polypeptides
WO2026028089A1 (en) 2024-07-29 2026-02-05 Novartis Ag Compositions and methods for the treatment of lysosomal acid lipase deficiency (lal-d)
WO2026037757A1 (en) 2024-08-13 2026-02-19 F. Hoffmann-La Roche Ag Modified aav particles
WO2026094009A1 (en) 2024-11-04 2026-05-07 Insmed Incorporated Compositions and methods for treating duchenne muscular dystrophy
WO2026132012A1 (en) 2024-12-20 2026-06-25 F. Hoffmann-La Roche Ag Aav particle processing using affinity chromatography with gradient elution
WO2026132139A1 (en) 2024-12-20 2026-06-25 F. Hoffmann-La Roche Ag Purification process for viral vectors
WO2026150302A1 (en) 2025-01-09 2026-07-16 Novartis Ag Novel aav rep/cap encoding constructs

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173418A (en) 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
DE69433922T2 (en) 1993-11-09 2005-07-28 Medical College Of Ohio, Toledo STABLE CELL LINE THAT IS ABLE TO EXPRESS THE REPLICATION GENE OF THE ADENOASSOCATED VIRUS
EP0733103B1 (en) 1993-11-09 2004-03-03 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
WO1996017947A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
FR2737730B1 (en) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc PROCESS FOR PURIFYING VIRUSES BY CHROMATOGRAPHY
JPH11511326A (en) 1995-08-30 1999-10-05 ジエンザイム コーポレイション Purification of adenovirus and AAV
JPH11514853A (en) 1995-09-08 1999-12-21 ジエンザイム コーポレイション Improved AAV vector for gene therapy
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
EP1696036B1 (en) 1996-09-06 2010-04-21 The Trustees of The University of Pennsylvania Use of recombinant adeno-associated virus in the manufacture of a medicament for gene therapy via muscle cells
US6756207B1 (en) 1997-02-27 2004-06-29 Cellomics, Inc. System for cell-based screening
CA2995542A1 (en) 1997-09-05 1999-03-11 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
JP2003518380A (en) * 1999-12-29 2003-06-10 ジェンザイム・コーポレイション Methods of using filter aids to separate viral vectors from nucleic acids and other cellular contaminants
JP2004514407A (en) 2000-04-28 2004-05-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア AAV5 capsid pseudotyped in heterologous capsid and recombinant AAV vector comprising AAV5 vector
EP1463805B1 (en) 2001-12-17 2014-10-22 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
JP4559429B2 (en) 2003-05-21 2010-10-06 ジェンザイム・コーポレーション Method for producing a recombinant AAV virion preparation substantially free of empty capsids
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
EP1682075A4 (en) 2003-11-07 2009-12-09 Univ Florida CULTURE AND DIFFERENTIATION OF NEURONAL PRECURSOR CELLS
ES2932278T3 (en) 2004-06-01 2023-01-17 Genzyme Corp Compositions and methods to prevent AAV vector aggregation
PT2548560E (en) 2005-06-23 2015-09-22 Isis Pharmaceuticals Inc COMPOSITIONS AND MODULATION METHODS OF THE SMN2 UNION EXCISION
EP2058401A1 (en) * 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
CA2729121C (en) 2008-06-30 2019-04-09 Centocor Ortho Biotech Inc. Differentiation of pluripotent stem cells
US9415121B2 (en) 2008-12-19 2016-08-16 Nationwide Children's Hospital Delivery of MECP2 polynucleotide using recombinant AAV9
WO2010071832A1 (en) 2008-12-19 2010-06-24 Nationwide Children's Hospital Delivery of polynucleotides across the blood brain barrier using recombinant aav9
US11219696B2 (en) * 2008-12-19 2022-01-11 Nationwide Children's Hospital Delivery of polynucleotides using recombinant AAV9
SI3988660T1 (en) 2009-05-02 2025-09-30 Genzyme Corporation Gene therapy for neurodegenerative disorders
KR20220084437A (en) 2009-06-17 2022-06-21 바이오젠 엠에이 인코포레이티드 Composition and methods for modulating of smn2 splicing in a subject
RU2664864C1 (en) 2009-12-23 2018-08-23 Янссен Байотек, Инк. Ways to increase expression of ngn3 and nkx6.1 in pancreatic endocrine cells
EP2529020B1 (en) * 2010-01-28 2018-04-25 The Children's Hospital of Philadelphia A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
DE102012007232B4 (en) 2012-04-07 2014-03-13 Susanne Weller Method for producing rotating electrical machines
RU2015100900A (en) 2012-06-14 2016-08-10 Янссен Байотек, Инк. TREATMENT OF PLURIPOTENT CELLS
CN104704123A (en) * 2012-06-21 2015-06-10 肌肉学研究协会 Gene therapy vectors for broad gene delivery
CA2880653C (en) 2012-08-01 2022-05-17 Nationwide Children's Hospital Intrathecal delivery of recombinant adeno-associated virus 9
BR112015027336A2 (en) 2013-05-01 2017-09-26 Genzyme Corp compositions and processes for treatment of spinal muscular atrophy
KR102069561B1 (en) 2013-07-11 2020-01-23 다카라 바이오 가부시키가이샤 Method for manufacturing non-enveloped virus
RU2664471C2 (en) 2013-07-26 2018-08-17 Юниверсити Оф Айова Рисерч Фаундейшн Methods and compositions for brain diseases treatment
RS63942B1 (en) 2013-08-27 2023-02-28 Res Inst Nationwide Childrens Hospital PRODUCTS AND PROCEDURES FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
JP2015092462A (en) 2013-09-30 2015-05-14 Tdk株式会社 Positive electrode and lithium ion secondary battery using the same
WO2015141521A1 (en) 2014-03-21 2015-09-24 株式会社日立国際電気 Substrate processing apparatus, semiconductor device manufacturing method, and recording medium
EP2933335A1 (en) 2014-04-18 2015-10-21 Genethon A method of treating peripheral neuropathies and motor neuron diseases
US10526583B2 (en) * 2014-07-02 2020-01-07 University Of Florida Research Foundation, Incorporated Compositions and methods for purifying recombinant adeno-associated virus
JP6197169B2 (en) 2014-09-29 2017-09-20 東芝メモリ株式会社 Manufacturing method of semiconductor device
JP6754361B2 (en) 2014-12-16 2020-09-09 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ Gene therapy for juvenile Batten disease
EP3054006A1 (en) * 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography
EP3054007A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
EP3387138B2 (en) * 2015-12-11 2026-05-27 The Trustees Of The University Of Pennsylvania Scalable purification method for aav9
PH12018502104B1 (en) * 2016-03-31 2024-03-27 Spark Therapeutics Inc Column-based fully scalable raav manufacturing process
US11253612B2 (en) * 2016-04-15 2022-02-22 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type II
EP3299456A1 (en) 2016-09-26 2018-03-28 Université de Strasbourg Recombinant dgkk gene for fragile x syndrome gene therapy
IL322146A (en) 2016-11-17 2025-09-01 Nationwide Childrens Hospital Inc Intrathecal delivery of recombinant adeno-associated virus encoding methyl-cpg binding protein 2
WO2019011817A1 (en) 2017-07-08 2019-01-17 Genethon Treatment of spinal muscular atrophy
EP4585229A3 (en) 2017-11-08 2026-01-14 Novartis AG Means and method for preparing viral vectors and uses of same
JP7478675B2 (en) 2018-06-08 2024-05-07 ノバルティス アーゲー Cell-Based Assays for Measuring the Potency of Drug Products

Also Published As

Publication number Publication date
AU2018365677C1 (en) 2025-09-11
JP2021502123A (en) 2021-01-28
AU2018365677B2 (en) 2025-04-03
BR112019013268A2 (en) 2019-12-17
KR20260052185A (en) 2026-04-17
CN119033965A (en) 2024-11-29
TW201930590A (en) 2019-08-01
AU2025203480B2 (en) 2026-04-09
CA3082136A1 (en) 2019-05-16
CL2024004045A1 (en) 2025-08-01
AU2026205424A1 (en) 2026-07-30
EP4585229A2 (en) 2025-07-16
MX2025009360A (en) 2025-09-02
AU2025203480A1 (en) 2025-06-05
KR20200086292A (en) 2020-07-16
IL274430B1 (en) 2024-09-01
MX2025001503A (en) 2025-03-07
MX2020004830A (en) 2020-11-11
SA520411930B1 (en) 2025-04-07
CO2020006900A2 (en) 2020-06-19
RU2020118557A (en) 2021-12-08
CN120501895A (en) 2025-08-19
JP2025017361A (en) 2025-02-05
EP3707264A1 (en) 2020-09-16
IL274430B2 (en) 2025-01-01
CN120505370A (en) 2025-08-19
IL274430A (en) 2020-06-30
RU2020118557A3 (en) 2022-04-15
CA3309109A1 (en) 2026-05-13
US12168777B2 (en) 2024-12-17
TWI827560B (en) 2024-01-01
CN111566220A (en) 2020-08-21
CL2025001440A1 (en) 2025-09-05
CL2020001193A1 (en) 2020-11-13
IL314692A (en) 2024-10-01
US20250066813A1 (en) 2025-02-27
JP7587422B2 (en) 2024-11-20
EP4585229A3 (en) 2026-01-14
WO2019094253A1 (en) 2019-05-16
SG11202004406VA (en) 2020-06-29
US20210317474A1 (en) 2021-10-14
AU2018365677A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
MX2025001503A (en) Means and method for preparing viral vectors and uses of same
MX2019007021A (en) Il-11ra antibodies.
MX2019007020A (en) Il-11 antibodies.
PH12018501159A1 (en) Composition and methods for immunooncology
MY191581A (en) Anti-pd-1 antibodies
HK1253403A1 (en) Genome editing vectors
MX2021006235A (en) ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF.
PH12018501378A1 (en) Compositions and methods for the treatment of hemoglobinopathies
MX2018016038A (en) Compounds and methods for modulating rna function.
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
MX2019002946A (en) Anti-pd-1(cd279) antibodies.
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
PH12018502456A1 (en) Anti-cd04 antibodies and their uses
SG10201803042PA (en) Anti-tim-3 antibodies
PH12017500858A1 (en) Mocrocyclic peptides useful as immunomodulators
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
EP3800248A3 (en) Crispr-cas-related methods, compositions and components for cancer immunotherapy
MX2017016169A (en) Anti-her2 antibodies and methods of use.
PH12018502137A1 (en) Anti-complement factor bb antibodies and uses thereof
EP4585268A3 (en) Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
MX2018004674A (en) Modulators of sestrin-gator2 interaction and uses thereof.
WO2016033437A3 (en) Polyethers, polyamines, polythioethers, and methods for making same
GB2568181A (en) Wheat
ZA201905895B (en) Kits and methods for preparing pathogen-inactivated platelet compositions
PL3618966T3 (en) Three-dimensional grinder, method for implementing same and uses thereof